Clinical trials: Plasmapheresis
Therapeutic Plasma Exchange
Comparison Between Centrifugation Based and Membrane Based Plasma Exchange
This study aims at comparing centrifugation based therapeutic plasma exchange (cTPE) versus membrane based therapeutic plasma exchange (mTPE) as regards performance, effectiveness and adverse events in patients indicated for TPE.
- Trial name
- NCT06652516
- Testing
- plasma exchange
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Alexandria University
Kidney Transplantation, Plasmapheresis
Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis
Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use, the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and elimination) of this therapy.
- Trial name
- NCT00203281
- Testing
- tacrolimus, mycophenolate mofetil, daclizumab
- Where
- 2 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Therapeutic Plasma Exchange, Covid19
RescuE pLAsma eXchange in Severe COVID-19
The spectrum of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to acute respiratory distress syndrome ("ARDS") and patient death.
- Trial name
- RELAX (NCT04685655)
- Testing
- Therapeutic plasma exchange
- Where
- 3 sites in Germany
- Volunteers
- 67 people
- Sponsor
- Heidelberg University
Hyperfibrinogenemia, Hemostatic Disorder
Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.
Therapeutic plasmapheresis causes changes in haemostasis by purifying many of the circulating factors involved. Few reliable data are available on these changes and most studies are limited to coagulation factor assays before and…
- Trial name
- APHERCOAG (NCT06571552)
- Testing
- Single Plasma Exchange followed by Double Filtration Plasmapheresis
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Antibody-mediated Rejection
Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR
Chronic-active antibody-mediated rejection (cAMR) due to de novo or pre-formed donor specific antibody (DSA) is currently considered the main cause of long-term allograft losses.Based on the aim of reducing or eliminating DSA…
- Trial name
- NCT03737136
- Testing
- Bortezomib
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Microplastic and Nanoplastic Particle Burden in Peripheral Blood, Double-Filtration Plasmapheresis
Evaluating DFPP for Microplastic and PFAS Reduction
This prospective, non-interventional, within-subject paired biomarker study will evaluate whether circulating microplastic and nanoplastic-associated particle concentrations and PFAS concentrations in peripheral blood change…
- Trial name
- DFPP-MNP (NCT07658443)
- Testing
- Double-Filtration Plasmapheresis With the IN300 Apheresis Device
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 20 people
- Sponsor
- Proxima Health, Inc.
Acute on Chronic Liver Failure
An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response
Rationale: Current understanding of the pathophysiology of ACLF suggests that unresolved injury, poor infection control, and liver regeneration result in persistent systemic inflammation and cytokine storm, which subsequently…
- Trial name
- NCT06276907
- Testing
- Plasma Exchange, Standard Medical Treatment
- Where
- India
- Volunteers
- 190 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
COVID-19
Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity
Many patients with Coronavirus Disease 2019 (COVID-19) have atypical blood clots. These blood clots can occur in either veins or arteries and be large, like in stroke or heart attack, or very tiny, called microthrombi.
- Trial name
- NCT04441996
- Testing
- Therapeutic plasma exchange (TPE), Standard of care
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University